Search Results

Background: EGFR-TKI inhibitors are established first line treatments (Tx) for metastatic non-small cell lung cancer (mNSCLC) harboring an EGFR sensitizing mutation. Upon EGFR-TKI resistance, there is little data to support the standard of care in

-assisted microdissection to generate epithelial cell–enriched material 51 to circumvent this problem. Perhaps of most interest, at least from a therapeutic standpoint, are studies of the epidermal growth factor receptor (EGFR) and the tyrosine kinase receptor, c

VEGF, and the anti-EGFR antibodies cetuximab and panitumumab. 2 – 4 All 3 of these agents are now approved for use in the first-line setting in patients with RAS / RAF WT mCRC. 5 – 7 Increased use of these agents has likely led to improvement in

Head and Neck Cancers Program, Smilow Cancer Hospital at Yale-New Haven. Dr. Burtness is a member of the NCCN Guidelines Panel for Head and Neck Cancers and the NCCN Task Force on Management of Dermatologic and Other Toxicities Associated with EGFR

chemotherapy, biologic agents are an important component of the arsenal against metastatic CRC (mCRC). Use of cetuximab and panitumumab, which are monoclonal antibodies targeting the epidermal growth factor receptor (EGFR), has evolved substantially over the

-approved drugs for use in colorectal cancer. Abbreviations: EGFR, epidermal growth factor receptor; TAS-102, trifluridine-tipiracil; VEGF, vascular endothelial growth factor. a VEGFR, BRAF, and others. The issue of cost remains a major concern in the treatment of

Background : Osimertinib is a third generation EGFR-TKI increasingly used as first-line treatment (Tx) for metastatic non-small cell lung cancer (mNSCLC) harboring an EGFR sensitizing mutation. This study characterized the subsequent line of

Background: Few studies have evaluated EGFR status concordance of multiple genomic tests using real-world data (RWD). Results of metastatic Non–Small Cell Lung Cancer (NSCLC) patients with multiple EGFR genomic tests within the ConcertAI Genome

Conference. 1 The list of mutations with approved targeted therapies includes EGFR mutations (present in 30%–40% of Asians 2 and 10%–20% of Caucasians), 3 ALK rearrangements (present in up to 7%), ROS1 rearrangements (1.7%), and BRAF mutations

Background : Epidermal growth factor receptor (EGFR) mutation status is a good predictor of response to EGFR tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). The existing data on the difference in survival outcome between